NO902995D0 - Stabilisert fgf-sammensetning samt fremstilling derav. - Google Patents

Stabilisert fgf-sammensetning samt fremstilling derav.

Info

Publication number
NO902995D0
NO902995D0 NO1990902995A NO902995A NO902995D0 NO 902995 D0 NO902995 D0 NO 902995D0 NO 1990902995 A NO1990902995 A NO 1990902995A NO 902995 A NO902995 A NO 902995A NO 902995 D0 NO902995 D0 NO 902995D0
Authority
NO
Norway
Prior art keywords
fgf protein
stabilized
composition
preparation
water
Prior art date
Application number
NO1990902995A
Other languages
English (en)
Other versions
NO902995L (no
Inventor
Yohko Akiyama
Minoru Yoshioka
Nobuyuki Kitamori
Original Assignee
Takeda Chemical Industries Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Chemical Industries Ltd filed Critical Takeda Chemical Industries Ltd
Publication of NO902995D0 publication Critical patent/NO902995D0/no
Publication of NO902995L publication Critical patent/NO902995L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1825—Fibroblast growth factor [FGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Inorganic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cardiology (AREA)
  • Zoology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
  • Fodder In General (AREA)
NO90902995A 1989-07-07 1990-07-04 Stabilisert fgf sammensetning samt fremstilling derav. NO902995L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP17622889 1989-07-07
JP13633390 1990-05-24

Publications (2)

Publication Number Publication Date
NO902995D0 true NO902995D0 (no) 1990-07-04
NO902995L NO902995L (no) 1991-01-08

Family

ID=26469955

Family Applications (1)

Application Number Title Priority Date Filing Date
NO90902995A NO902995L (no) 1989-07-07 1990-07-04 Stabilisert fgf sammensetning samt fremstilling derav.

Country Status (14)

Country Link
US (1) US5189148A (no)
EP (1) EP0406856B1 (no)
JP (1) JP2536247B2 (no)
CN (1) CN1049106A (no)
AT (1) ATE102044T1 (no)
AU (1) AU632344B2 (no)
CA (1) CA2020654A1 (no)
DE (1) DE69006947T2 (no)
DK (1) DK0406856T3 (no)
ES (1) ES2062206T3 (no)
FI (1) FI903440A0 (no)
HU (1) HU205862B (no)
IE (1) IE902470A1 (no)
NO (1) NO902995L (no)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5981485A (en) 1997-07-14 1999-11-09 Genentech, Inc. Human growth hormone aqueous formulation
US5763394A (en) * 1988-04-15 1998-06-09 Genentech, Inc. Human growth hormone aqueous formulation
US5202311A (en) * 1988-08-19 1993-04-13 Children's Medical Center Corporation Stabilized fgf composition
GB9015824D0 (en) * 1990-07-18 1990-09-05 Erba Carlo Spa Stable pharmaceutical compositions containing a fibroblast growth factor
US5714458A (en) * 1990-07-18 1998-02-03 Farmitalia Carlo Erba S.R.L. Stable pharmaceutical compositions containing a fibroblast growth factor
US5500409A (en) * 1990-10-01 1996-03-19 Thomas Jefferson University Method for inhibiting collagen synthesis by keloid fibroblasts
TW209174B (no) 1991-04-19 1993-07-11 Takeda Pharm Industry Co Ltd
US6613332B1 (en) 1991-06-21 2003-09-02 The University Of Cincinnati Oral administration of therapeutic proteins
EP0590060B1 (en) 1991-06-21 1997-09-17 University Of Cincinnati Orally administrable therapeutic proteins and method of making
DE4121043A1 (de) * 1991-06-26 1993-01-07 Merck Patent Gmbh Knochenersatzmaterial mit fgf
CA2080538A1 (en) * 1991-10-21 1993-04-22 Joseph V. Bondi Lyophilized acidic fibroblast growth factor
EP0539087A1 (en) * 1991-10-21 1993-04-28 Merck & Co. Inc. Stabilized topical acidic fibroblast growth factor formulation
US5580578A (en) * 1992-01-27 1996-12-03 Euro-Celtique, S.A. Controlled release formulations coated with aqueous dispersions of acrylic polymers
US5482929A (en) * 1991-12-26 1996-01-09 Kaken Pharmaceutical Co., Ltd. Composition of stabilized fibroblast growth factor
US7070806B2 (en) * 1992-01-27 2006-07-04 Purdue Pharma Lp Controlled release formulations coated with aqueous dispersions of acrylic polymers
US5348941A (en) * 1992-04-01 1994-09-20 Merck & Co., Inc. Stabilizers for fibroblast growth factors
SE9201073D0 (sv) * 1992-04-03 1992-04-03 Kabi Pharmacia Ab Protein formulation
DE4242889A1 (de) * 1992-12-18 1994-06-23 Merck Patent Gmbh Hohlendoprothesen mit Knochenwachstumsfördernder Füllung
JP3349535B2 (ja) * 1993-01-12 2002-11-25 フロイント産業株式会社 球形顆粒の製造方法
US5331095A (en) * 1993-04-12 1994-07-19 Scios Nova Inc. Process for purification of basic fibroblast growth factor
DE69427908T2 (de) * 1993-05-31 2001-11-22 Kaken Pharma Co Ltd Eine gelpräparation aus vernetzter gelatine, die einen basischen wachstumsfaktor für fibroblasten enthält
JPH07112940A (ja) * 1993-08-26 1995-05-02 Takeda Chem Ind Ltd 徐放性非経口投与製剤およびその製造方法
EP0943336A1 (en) * 1996-09-04 1999-09-22 Dott Research Laboratory Peptide-containing pharmaceutical compositions for oral administration
US6692961B1 (en) 1996-10-11 2004-02-17 Invitrogen Corporation Defined systems for epithelial cell culture and use thereof
US5851579A (en) * 1996-10-28 1998-12-22 Eastman Chemical Company Aqueous enteric coating compositions
CA2395534A1 (en) * 1999-06-07 2000-12-14 Fibersugar Aps Particulate fibre composition
US20030228288A1 (en) 1999-10-15 2003-12-11 Scarborough Nelson L. Volume maintaining osteoinductive/osteoconductive compositions
GEP20053427B (en) 1999-12-23 2005-01-25 Pfizer Prod Inc Pharmaceutical Compositions Providing Enhanced Drug Concentrations
JP4711520B2 (ja) * 2000-03-21 2011-06-29 日本ケミカルリサーチ株式会社 生理活性ペプチド含有粉末
US9387094B2 (en) 2000-07-19 2016-07-12 Warsaw Orthopedic, Inc. Osteoimplant and method of making same
US7323193B2 (en) 2001-12-14 2008-01-29 Osteotech, Inc. Method of making demineralized bone particles
JP2005505351A (ja) 2001-10-12 2005-02-24 オステオテック インコーポレーテッド 改善された骨移植片
FR2836011B1 (fr) * 2002-02-20 2004-05-14 Goemar Lab Sa Agent pour la stimulation des defenses naturelles des plantes et procede pour sa mise en oeuvre
JP4250087B2 (ja) * 2002-04-01 2009-04-08 科研製薬株式会社 塩基性線維芽細胞増殖因子含有歯科用粘稠製剤
CA2528086C (en) 2003-06-11 2013-01-08 Osteotech, Inc. Osteoimplants and methods for their manufacture
ES2403357T3 (es) 2003-12-11 2013-05-17 Isto Technologies Inc. Sistema de cartílago particulado
US20070128685A1 (en) * 2005-07-01 2007-06-07 Rodolfo Faudoa Methods and compositions for cell culture
US20070004036A1 (en) * 2005-07-01 2007-01-04 Rodolfo Faudoa Methods and compositions for keratinocyte culture
US20070003541A1 (en) * 2005-07-01 2007-01-04 Rodolfo Faudoa Methods and compositions for therapeutics
JP5292533B2 (ja) 2005-08-26 2013-09-18 ジンマー・インコーポレイテッド インプラントおよび関節疾患の治療、置換および治療方法
WO2007056671A1 (en) 2005-11-02 2007-05-18 Osteotech, Inc. Hemostatic bone graft
US20080154233A1 (en) * 2006-12-20 2008-06-26 Zimmer Orthobiologics, Inc. Apparatus for delivering a biocompatible material to a surgical site and method of using same
US8163549B2 (en) 2006-12-20 2012-04-24 Zimmer Orthobiologics, Inc. Method of obtaining viable small tissue particles and use for tissue repair
US20090012629A1 (en) 2007-04-12 2009-01-08 Isto Technologies, Inc. Compositions and methods for tissue repair
AU2009308191A1 (en) 2008-10-24 2010-04-29 Warsaw Orthopedic, Inc. Compositions and methods for promoting bone formation
KR20150003233A (ko) * 2012-03-30 2015-01-08 아지노모토 가부시키가이샤 황산화 화합물을 포함하는 줄기 세포 증식용 배지
US20140178343A1 (en) 2012-12-21 2014-06-26 Jian Q. Yao Supports and methods for promoting integration of cartilage tissue explants
CN108779158A (zh) 2015-11-27 2018-11-09 马萨里克大学 热稳定性fgf2多肽、其用途
JP2021138648A (ja) * 2020-03-04 2021-09-16 武田薬品工業株式会社 経口固形製剤
EP4183796A1 (en) 2021-11-19 2023-05-24 Enantis s.r.o. Thermostable fgf10 polypeptide or fragment thereof use thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ222413A (en) * 1986-11-05 1991-06-25 Ethicon Inc Compositions containing a polypeptide growth factor and a water-soluble cellulose polymer stabiliser
US4717717A (en) * 1986-11-05 1988-01-05 Ethicon, Inc. Stabilized compositions containing epidermal growth factor
JP2526965B2 (ja) * 1987-02-24 1996-08-21 武田薬品工業株式会社 ムテイン，ｄｎａおよびその用途
NZ226171A (en) * 1987-09-18 1990-06-26 Ethicon Inc Gel formulation containing polypeptide growth factor
NZ226170A (en) * 1987-09-18 1990-07-26 Ethicon Inc Stable freeze-dried pharmaceutical composition containing epidermal growth factor

Also Published As

Publication number Publication date
EP0406856A2 (en) 1991-01-09
AU5879990A (en) 1991-01-10
CN1049106A (zh) 1991-02-13
EP0406856A3 (en) 1991-04-10
US5189148A (en) 1993-02-23
EP0406856B1 (en) 1994-03-02
FI903440A0 (fi) 1990-07-06
DK0406856T3 (da) 1994-07-04
CA2020654A1 (en) 1991-01-08
HU205862B (en) 1992-07-28
ES2062206T3 (es) 1994-12-16
ATE102044T1 (de) 1994-03-15
NO902995L (no) 1991-01-08
DE69006947D1 (de) 1994-04-07
AU632344B2 (en) 1992-12-24
HU904116D0 (en) 1990-12-28
JP2536247B2 (ja) 1996-09-18
JPH04128239A (ja) 1992-04-28
DE69006947T2 (de) 1994-08-25
IE902470A1 (en) 1991-02-13
HUT54895A (en) 1991-04-29

Similar Documents

Publication Publication Date Title
NO902995D0 (no) Stabilisert fgf-sammensetning samt fremstilling derav.
US5565427C1 (en) Stabilized factor viii preparations
FI884051A (fi) Menetelmä stabiloitujen humaaniproteiinivalmisteiden valmistamiseksi
SE9002522D0 (sv) Metod foer framstaellning av en farmaceutisk komposition i form av mikropartiklar
ZA907338B (en) Thienylcarboxylates of amino alcohols
IL89503A0 (en) Taxol derivatives,pharmaceutical compositions containing the same and process for the preparation thereof
AU1141288A (en) Production of proteins in active forms
NO922953D0 (no) Rekombinant fremstilt blodfaktorer og fremgangsmaate for ekspresjon av blodfaktorene, samt vacciniavirusrekombinanter
ATE116524T1 (de) Nematozide zubereitungen.
DE69027472D1 (de) Arylsubstituierte Rhodaninderivate
NO895194D0 (no) Fremgangsmaate for fremstilling av piperidinderivater.
DK284988D0 (da) Fremgangsmaade til fremstilling af den 2,2-paracyclophandimer, der anvendes til fremstilling af paylen
EP0254239A3 (en) Optically pure 1,3-dioxenones, methods for preparing same and use thereof
DE3887212D1 (de) Verfahren zur Herstellung von Derivaten von 6,7-Diazyl-7-desacetylforskolin.
ATE96331T1 (de) Fr115224 enthaltende zusammensetzung fuer eine parenterale verabreichung.
ATE112264T1 (de) Verfahren zur herstellung von 2,6-di-t-butyl-4- merkaptophenol.
AU6764790A (en) 13-beta-phenethylthio-milbemycin derivatives
EP0271964A3 (en) Method for preparing protein hydrolysates soluble in an acid environment, and the hydrolysates obtained
DE69009651D1 (de) Verfahren zur Herstellung von 3,4-Dihydrocumarinderivaten.
NO872624D0 (no) Fremgangsmaate for fremstilling av 3,7-dihydro-3-n-propyl-1h-purin-2,6-dion.
DE3869895D1 (de) Cephalosporinderivate mit verbesserter pharmakokinetik, verfahren zur ihrer herstellung, sie enthaltende pharmazeutische praeparate und zwischenverbindung.
NO902405D0 (no) Vevplasminogenaktivatorderivat, dna-sekvens og ekspresjonsplasmid, samt fremgangsmaate for fremstilling av plasmidet.
SE8605535D0 (sv) Cellsystem, dess framstellning och anvendning
NO901860D0 (no) Innkapslet syresammensetning samt fremgangsmaate for fremstilling av slik syresammensetning.
IT8619653A0 (it) Procedimento per la produzione di bussole a struttura perfezionara, per l'unione di parti in legno.